Previous Close | 29.50 |
Open | 29.90 |
Bid | 29.50 x N/A |
Ask | 30.00 x N/A |
Day's Range | 29.00 - 30.00 |
52 Week Range | 4.72 - 33.00 |
Volume | 468,907 |
Avg. Volume | 2,716,418 |
Market Cap | 196.804M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.20 |
Earnings Date | Sep 30, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Federal government increasing state allotment of vaccines. Meanwhile, U.K. begins first human challenge trials.
Open Orphan (AIM:ORPH) announced the world’s first COVID-19 characterization study has received ethics approval in the UK.
Scientists are studying booster shots and/or new vaccines that can protect against the evolving virus or specific strains as coronavirus variants spread around the globe.